Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Wednesday that it will work with Curia Global, a contract development and manufacturing organisation (CDMO), to provide formulation development services for Anixa's investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial.
The vaccine is being developed in collaboration with Cleveland Clinic.
Under the collaboration, Curia will support the development of a formulation designed to optimise the vaccine's stability, consistency, and suitability for clinical manufacturing. Anixa said that this work represents an important step in its preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.
Anixa's investigational breast cancer vaccine is designed to stimulate the immune system to recognise alpha-lactalbumin, a protein expressed in many breast cancers. According to the company, the vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favourable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. Anixa is preparing to advance the vaccine into Phase 2 clinical development to further evaluate its potential clinical benefits.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment